Thus, the data in Figures 1–7 validate the combination of (ruxolitinib + ERBB1/2/4 inhibitor) and of (ruxolitinib + MMF) as putative anti-cancer therapies for mammary tumors (33). This evidence concerns the gene EGFR and breast cancer.